Kidney Graft Function Under the Immunosuppression Strategies
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 140 participants.
Also called NCT01817322
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 140 participants
- Sponsor
- Registry
-
NCT01817322
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Not reported
- Registry status
- Completed
Technical summary
Registry record NCT01817322. Randomized; no masking; primary purpose treatment. Start 2011-06 (registry gives no type); primary completion 2013-08 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Kidney Graft Function Under the Immunosuppression Strategies
- Acronym
- MyLowCsA
- Condition
- Chronic Renal Disease
- Intervention (Drug)
- Standard Dose of Myfortic and Reduced Dose of Myfortic
- Intervention (Drug)
- Prednisolone OR methylprednisolone OR deflazacort injected both control group and experimental group
- Intervention (Drug)
- Basiliximab injected both control group and experimental group
- Lead sponsor
- Samsung Medical Center
Record details
- Record id
cardio:ct-nct01817322- Content hash
eae0cea0cad3b4ddbd2f7b0c9b3b1e84beb04a128a690d22b4dfe512838e2d06